Outpatient monitoring of patients with lipoprotein metabolism disorders and other lipidemias by a general practitioner in primary care. Guidelines
O. M. Drapkina,
S. A. Boytsov,
A. I. Ershova,
R. N. Shepel,
O. A. Osipova,
A. N. Meshkov,
A. V. Blokhina,
P. V. Ipatov,
T. V. Balakhonova,
E. D. Savchenko https://doi.org/10.15829/1728-8800-2024-4285
EDN: LDSYMS
- Р Р‡.МессенРТвЂВВВВВВВВжер
- РћРТвЂВВВВВВВВнокласснРСвЂВВВВВВВВРєРСвЂВВВВВВВВ
- LiveJournal
- Telegram
- ВКонтакте
- РЎРєРѕРїРСвЂВВВВВВВВровать ссылку
Full Text:
Abstract
The guideline describes the management of outpatient monitoring of patients with lipid metabolism disorders by a general practitioner. The following is presented: the approximate volume and frequency of paraclinical investigations, information on the diagnosis, treatment and prevention of disease complications. As practical experience is accumulated, the guidelines will be adjusted.
The guidelines are intended for general practitioners, family doctors, as well as for mid-level health providers working with the above-mentioned doctors, for paramedics performing the doctor functions. The guidelines can be used by public health physicians, heads of primary health care facilities and their divisions.
About the Authors
O. M. Drapkina
National Medical Research Center for Therapy and Preventive Medicine; Chazov National Medical Research Center for Cardiology; Russian Society for the Prevention of Noncommunicable Diseases
Russian Federation
Russian Federation
S. A. Boytsov
National Medical Research Center for Therapy and Preventive Medicine; Chazov National Medical Research Center for Cardiology; Russian Society for the Prevention of Noncommunicable Diseases
Russian Federation
Russian Federation
A. I. Ershova
National Medical Research Center for Therapy and Preventive Medicine; Chazov National Medical Research Center for Cardiology; Russian Society for the Prevention of Noncommunicable Diseases
Russian Federation
Russian Federation
R. N. Shepel
National Medical Research Center for Therapy and Preventive Medicine; Chazov National Medical Research Center for Cardiology; Russian Society for the Prevention of Noncommunicable Diseases
Russian Federation
Russian Federation
O. A. Osipova
National Medical Research Center for Therapy and Preventive Medicine; Chazov National Medical Research Center for Cardiology; Russian Society for the Prevention of Noncommunicable Diseases
Russian Federation
Russian Federation
A. N. Meshkov
National Medical Research Center for Therapy and Preventive Medicine; Chazov National Medical Research Center for Cardiology; Russian Society for the Prevention of Noncommunicable Diseases
Russian Federation
Russian Federation
A. V. Blokhina
National Medical Research Center for Therapy and Preventive Medicine; Chazov National Medical Research Center for Cardiology; Russian Society for the Prevention of Noncommunicable Diseases
Russian Federation
Russian Federation
P. V. Ipatov
National Medical Research Center for Therapy and Preventive Medicine; Chazov National Medical Research Center for Cardiology; Russian Society for the Prevention of Noncommunicable Diseases
Russian Federation
Russian Federation
T. V. Balakhonova
National Medical Research Center for Therapy and Preventive Medicine; Chazov National Medical Research Center for Cardiology; Russian Society for the Prevention of Noncommunicable Diseases
Russian Federation
Russian Federation
E. D. Savchenko
National Medical Research Center for Therapy and Preventive Medicine; Chazov National Medical Research Center for Cardiology; Russian Society for the Prevention of Noncommunicable Diseases
Russian Federation
Russian Federation
References
1. Ezhov MV, Kukharchuk VV, Sergienko IV, et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):5471. (In Russ.) https://doi.org/10.15829/1560-40712023-5471.
2. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41:111-88. https://doi.org/10.1093/eurheartj/ehz455.
3. Drapkina OM, Kontsevaya AV, Kalinina AM, et al. Prevention of chronic non-communicable diseases in the Russian Federation. National guidelines. Cardiovascular Therapy and Prevention. 2022;21(4):3235. (In Russ.) https://doi.org/10.15829/17288800-2022-3235.
4. Akchurin RS, Alekyan BG, Aronov DM, et al. 2020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):4076. (In Russ.) https://doi.org/10.15829/1560-4071-2020-4076.
5. Bockeria LA, Pokrovsky AV, Akchurin RS, et al. National guidelines for the diagnosis and treatment of lower extremity artery diseases. Moscow. 2019. 89 p. (In Russ.) EDN LULSLW.
6. Blokhina AV, Ershova AI, Meshkov AN, Drapkina OM. Familial dysbetalipoproteinemia: highly atherogenic and underdiagnosed disorder. Cardiovascular Therapy and Prevention. 2021; 20(6):2893. (In Russ.) https://doi.org/10.15829/1728-8800-2021-2893.
7. Blokhina AV, Ershova AI, Kiseleva AV, et al. Applicability of Diagnostic Criteria and High Prevalence of Familial Dysbetalipoproteinemia in Russia: A Pilot Study. Int J Mol Sci. 2023;24(17):13159. https://doi.org/10.3390/ijms241713159.
8. Ershova AI, Al Rashi DO, Ivanova AA, et al. Secondary hyperlipidemias: etiology and pathogenesis. Russian Journal of Cardiology. 2019;(5):74-81. (In Russ.) https://doi.org/10.15829/1560-4071-2019-5-74-81.
9. Dedov II, Shestakova MV, Mayorov AYu. Standards of specialized diabetes care.2023.11th Edition. Diabetes mellitus. 2023;26(2S):1-157. (In Russ.) https://doi.org/10.14341/DM13042.
10. Balakhonova TV, Ershova AI, Ezhov MV, et al. Focused vascular ultrasound. Consensus of Russian experts. Cardiovascular Therapy and Prevention. 2022;21(7):3333. (In Russ.) https://doi.org/10.15829/1728-8800-2022-3333.
11. Koshechkin VA, Malyshev PP, Rozhkova TA. Medical and genetic counseling for dyslipidemia: a guide for doctors. Publishing house GEOTAR Media. 2021 264 p. (In Russ.) ISBN: 978-59704-6191-4.
12. Haralambos K, Whatley SD, Edwards R, et al. Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales. Atherosclerosis. 2015;240(1):190-6. https://doi.org/10.1016/j.atherosclerosis.2015.03.003.
13. Svinin GE, Kutsenko VA, Shalnova SA, et al. Validation of SCORE2 on a sample from the Russian population and adaptation for the very high cardiovascular disease risk region. PLoS One. 2024;19(4):e0300974. https://doi.org/10.1371/journal.pone.0300974.
14. Saba L, Cau R, Murgia A, et al. Carotid Plaque-RADS: A Novel Stroke Risk Classification System. JACC Cardiovasc Imaging. 2024;17(1):62-75. https://doi.org/10.1016/j.jcmg.2023.09.005.
15. Chernyavsky MA, Irtyuga OB, Yanishevsky SN, et al. Russian consensus statement on the diagnosis and treatment of patients with carotid stenosis. Russian Journal of Cardiology. 2022;27(11):5284. (In Russ.) https://doi.org/10.15829/1560-4071-2022-5284.
16. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):670-1681. https://doi.org/10.1016/S01406736(10)61350-5.
17. Blokhina AV, Ershova AI, Meshkov AN, et al. Lipid Clinic is an Efficacious Model of Preventive Medicine. Rational Pharmacotherapy in Cardiology. 2021;17(1):4-10. (In Russ.) https://doi.org/10.20996/1819-6446-2021-01-02.
18. Blokhina AV, Ershova AI, Kopylova OV, et al. Actual nutrition in adults with familial hypercholesterolemia. Voprosy pitaniia [Problems of Nutrition]. 2023;92(4):49-58. (In Russ.) https://doi.org/10.33029/00428833-2023-92-4-49-58.
19. Mozaffarian D. Natural trans fat, dairy fat, partially hydrogenated oils, and cardiometabolic health: the Ludwigshafen Risk and Cardiovascular Health Study. Eur Heart J. 2016;37(13):1079-81. https://doi.org/10.1093/eurheartj/ehv595.
20. Chen M, Li Y, Sun Q, et al. Dairy fat and risk of cardiovascular disease in 3 cohorts of US adults. Am J Clin Nutr. 2016; 104(5):1209-17. https://doi.org/10.3945/ajcn.116.134460.
21. Farnier M, Santos RD, Cosin-Sales J, et al. Projected impact of treatment intensification with statin, ezetimibe, and statin plus ezetimibe fixed-dose combination on MACE across six countries. Eur J Prev Cardiol. 2022;29(17):2264-71.
22. Blokhina AV, Ershova AI, Limonova AS, et al. PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center. Rational Pharmacotherapy in Cardiology. 2021;17(6):808-15. (In Russ.) https://doi.org/10.20996/1819-6446-2021-12-01.
23. Drapkina OM, Drozdova LYu, Ipatov PV, et al. Follow-up monitoring of second health status group persons with high and very high cardiovascular risk. Guidelines. Cardiovascular Therapy and Prevention. 2024;23(6):4076. (In Russ.) https://doi.org/10.15829/1728-8800-2024-4076. EDN WNZCUQ.
Review
For citations:
Drapkina O.M., Boytsov S.A., Ershova A.I., Shepel R.N., Osipova O.A., Meshkov A.N., Blokhina A.V., Ipatov P.V., Balakhonova T.V., Savchenko E.D. Outpatient monitoring of patients with lipoprotein metabolism disorders and other lipidemias by a general practitioner in primary care. Guidelines. Cardiovascular Therapy and Prevention. 2024;23(12):4285. (In Russ.) https://doi.org/10.15829/1728-8800-2024-4285. EDN: LDSYMS
Views:
497
ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)
ISSN 2619-0125 (Online)
Email this article 
